Further study details as provided by GlaxoSmithKline:

Primary Outcomes: Hair growth assessed by macrophotographic technique (hair count) in the vertex at 6 months.
Secondary Outcomes: Subject assessment of change in hair growth and loss. Panel and investigator photographic assessment of change in hair growth Hormone measurements of LH at screening and DHT, testosterone, TSH, and T4. Assessment of sexual function
Expected Total Enrollment:  150

Ages Eligible for Study:  18 Years   -   49 Years,  Genders Eligible for Study:  Male

Criteria

Inclusion criteria:

• Diagnosis of Male Pattern Hair Loss classified as type IIIv, IV, or V utilising the modified Norwood-Hamilton classification (N.B. types IVa and Va are excluded)

Exclusion criteria:

• Global scalp hair thinning, including occipital areas
• Scarring of the scalp or any other condition or disease of the scalp or hair, including diseases of the hair shaft and inability to discontinue use of hair weaving.
• Subjects who use hair colourants/hair dyes, or have the remaining traces of colourants in their hair.
• Use of finasteride or other 5 AR inhibitors within the 12 months prior to screening.
• Previous use of dutasteride.
• Use of phytotherapy (e.g. saw palmetto) within 8 weeks prior to screening.
• Use of the following during the 6 months prior to screening:
  • Minoxidil (oral or topical)
  • Drugs with anti-androgenic properties (e.g., cyproterone acetate, spironolactone, ketoconazole, flutamide, bicalutamide). Cimetidine cannot be used during the study but is not an excluded drug when used during the previous 6 months.
  • Topical estrogen, progesterone
  • Tamoxifen
  • Drugs potentially causing hypertrichosis (e.g., cyclosporine, diazoxide, phenytoin psoralens)
  • Anabolic steroids
  • Lithium and phenothiazines

Please refer to this study by ClinicalTrials.gov identifier  NCT00441116

Korea, Republic of
      GSK Clinical Trials Call Center, Seoul,  110-744,  Korea, Republic of; Recruiting
      GSK Clinical Trials Call Center, Seoul,  140-702,  Korea, Republic of; Not yet recruiting
      GSK Clinical Trials Call Center, Seoul,  134-090,  Korea, Republic of; Recruiting
      GSK Clinical Trials Call Center, Wonju,  220-701,  Korea, Republic of; Recruiting

Study chairs or principal investigators

GSK Clinical Trials, M.D., Ph.D.,  Study Director,  GlaxoSmithKline